Table I.
Comparison of clinical characteristics of prostate cancer patients in TCGA-PRAD database.
| Expression of LTBP2 | ||||
|---|---|---|---|---|
| Characteristics | Total | Low (%) | High (%) | P-value |
| Total samples, n | 449 | 249 | 250 | |
| Age, n (%) | 0.054 | |||
| ≤60 | 324 | 123 (24.6) | 101 (20.2) | |
| >60 | 275 | 126 (25.3) | 149 (29.9) | |
| T stage, n (%) | <0.001 | |||
| T2 | 189 | 117 (23.8) | 72 (14.6) | |
| T3 | 292 | 128(26) | 164 (33.3) | |
| T4 | 11 | 2 (0.4) | 9 (1.8) | |
| N stage, n (%) | 0.120 | |||
| N0 | 347 | 168 (39.4) | 179(42) | |
| N1 | 79 | 30(7) | 49 (11.5) | |
| M stage, n (%) | 0.99 | |||
| M0 | 455 | 228 (49.8) | 227 (49.6) | |
| M1 | 3 | 2 (0.4) | 1 (0.2) | |
| PSA (ng/ml), n (%) | 0.99 | |||
| <4 | 415 | 207 (46.8) | 208 (47.1) | |
| ≥4 | 27 | 14 (3.2) | 13 (2.9) | |
| Gleason score, n (%) | <0.001 | |||
| 6 | 46 | 33 (6.6) | 13 (2.6) | |
| 7 | 247 | 142 (28.5) | 105(21) | |
| 8 | 64 | 28 (5.6) | 36 (7.2) | |
| 9 | 138 | 45(9) | 93 (18.6) | |
| 10 | 4 | 1 (0.2) | 3 (0.6) | |
TCGA, The Cancer Genome ATLAS; PRAD, prostate adenocarcinoma; LTBP2, latent transforming growth factor β-binding protein 2; T, tumor, N, node; M, metastasis; PSA, prostate-specific antigen.